Jun 23, 2025 7:00 am EDT Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions
Jun 17, 2025 7:00 am EDT Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions
May 19, 2025 5:00 am EDT Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
May 13, 2025 7:00 am EDT Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
May 8, 2025 4:01 pm EDT Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
May 7, 2025 7:00 am EDT Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025